NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
NASDAQ: MDGL INVESTIGATION ALERT: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.
Whistleblower Complaint filed against Madrigal
On November 3, 2026, Madrigal disclosed in its quarterly report that on October 9, 2026, the company’s former Senior Vice President and Head of Clinical Development filed a whistleblower complaint against Madrigal alleging that he reported to Madrigal’s Senior Executive Leadership “adverse safety findings and unreproducible efficacy data” for the company’s only approved drug, Rezdiffra. Specifically, “that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with their own source data, and allowing an unblinded Board member… to control the adjudication of clinical outcomes.”
Madrigal’s Stock Drops Over 8%
Following the news of the whistleblower complaint against Madrigal, the company’s stock price fell over 8%.
Investors who purchased Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) securities and experienced losses may have legal rights under the federal securities laws.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Madrigal Pharmaceuticals, Inc. securities and have lost money on your investment, please provide your information here: https://www.ktmc.com/mdgl-madrigal-pharmaceuticals-inc-investigation?utm_campaign=hc?utm_source=Businesswire&utm_medium=pressrelease&utm_campaign=aur&mktm=PR
There is no cost or obligation to speak with an attorney.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including being recognized in Chambers & Partners USA 2026 as a Band 1 Top Firm in Securities and Class Actions, Legal 500’s Tier 1 Rankings for Securities and M&A Litigation, The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Jonathan Naji, Esq.
280 King of Prussia Road
Radnor, PA 19087
(484) 270-1453
info@ktmc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20261106558786/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
United States